2020
DOI: 10.1002/dta.2728
|View full text |Cite
|
Sign up to set email alerts
|

Anabolic and lipolytic actions of beta2‐agonists in humans and antidoping challenges

Abstract: Inhaled beta 2 -adrenoceptor agonists (beta 2 -agonists) are among the most used substances in competitive sports. The 2020 Prohibited List issued by the World Anti-Doping Agency restricts use of all selective and non-selective beta 2 -agonists in-and out-of competition with few exemptions. Formoterol, salbutamol, and salmeterol are allowed by inhalation within defined dosing limits. These restrictions are in place because supratherapeutic use of beta 2 -agonist has the potential to be anabolic and to enhance … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
69
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

citations
Cited by 41 publications
(74 citation statements)
references
References 148 publications
(221 reference statements)
3
69
0
Order By: Relevance
“…Clenbuterol is placed in the WADA list of doping agents in group S1 – Anabolic Agents [13] . There are known cases of detection of clenbuterol in professional athletes during anti‐doping control [231–235] …”
Section: Ingredients Prohibited By Wadamentioning
confidence: 99%
“…Clenbuterol is placed in the WADA list of doping agents in group S1 – Anabolic Agents [13] . There are known cases of detection of clenbuterol in professional athletes during anti‐doping control [231–235] …”
Section: Ingredients Prohibited By Wadamentioning
confidence: 99%
“…A continuously growing body of evidence exists that the aerobic performance does not appear to be acutely affected by the use of β 2 ‐agonists such as terbutaline 126–128 . Conversely, β 2 ‐agonists such as salbutamol and salmeterol can enhance anaerobic performance concerning disciplines such as, for example, sprint 129–131 but not necessarily when used at dosages permitted according to WADA's regulations 132 . These regulations include maximum permitted doses for formoterol, salbutamol, and salmeterol, 10 with corresponding urinary thresholds existing for formoterol and salbutamol, 133 while salmeterol is reported as AAF when exceeding 50% of the MRPL (i.e., 10 ng/ml).…”
Section: β2‐agonistsmentioning
confidence: 99%
“…The need for dosing limits of beta 2 -agonists has become increasingly pertinent given the potential performance-enhancing effects when used at high doses. [4][5][6][7][8][9][10][11] For formoterol and salbutamol, [12][13][14][15][16][17][18][19][20] urine thresholds have been in place for years to control for supratherapeutic misuse exceeding the dosing limits. However, as data on urine pharmacokinetics of salmeterol are limited, [21][22][23] no urine threshold has been established for this beta 2 -agonist.…”
Section: Introductionmentioning
confidence: 99%
“…One such beta 2 ‐agonist is salmeterol, which is allowed by inhalation at therapeutic doses up to 200 μg daily. The need for dosing limits of beta 2 ‐agonists has become increasingly pertinent given the potential performance‐enhancing effects when used at high doses 4–11 . For formoterol and salbutamol, 12–20 urine thresholds have been in place for years to control for supratherapeutic misuse exceeding the dosing limits.…”
Section: Introductionmentioning
confidence: 99%